X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (177) 177
oncology (148) 148
female (114) 114
lung neoplasms - drug therapy (110) 110
index medicus (108) 108
male (104) 104
middle aged (102) 102
aged (100) 100
carcinoma, non-small-cell lung - drug therapy (100) 100
chemotherapy (83) 83
adult (80) 80
lung neoplasms - pathology (73) 73
antineoplastic combined chemotherapy protocols - therapeutic use (61) 61
carcinoma, non-small-cell lung - pathology (52) 52
lung neoplasms - genetics (52) 52
treatment outcome (51) 51
respiratory system (49) 49
carcinoma, non-small-cell lung - genetics (46) 46
lung cancer (43) 43
cancer (41) 41
lung cancer, non-small cell (40) 40
antineoplastic agents - therapeutic use (39) 39
aged, 80 and over (38) 38
disease-free survival (37) 37
lung neoplasms - mortality (37) 37
neoplasm staging (35) 35
non-small cell lung cancer (34) 34
carcinoma, non-small-cell lung - mortality (32) 32
protein kinase inhibitors - therapeutic use (31) 31
nsclc (30) 30
survival (30) 30
cisplatin - administration & dosage (29) 29
care and treatment (28) 28
hematology, oncology and palliative medicine (27) 27
mutation (27) 27
prognosis (26) 26
survival analysis (26) 26
receptor, epidermal growth factor - genetics (24) 24
gefitinib (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
cisplatin (20) 20
deoxycytidine - analogs & derivatives (20) 20
disease progression (20) 20
erlotinib (20) 20
metastasis (20) 20
open-label (20) 20
survival rate (20) 20
tumors (20) 20
docetaxel (19) 19
trial (19) 19
lung neoplasms - metabolism (18) 18
non-small-cell lung cancer (18) 18
retrospective studies (18) 18
carcinoma, non-small-cell lung - metabolism (17) 17
egfr (17) 17
pulmonary/respiratory (17) 17
acquired-resistance (16) 16
carboplatin - administration & dosage (16) 16
deoxycytidine - administration & dosage (16) 16
gemcitabine (16) 16
italy (16) 16
adenocarcinoma - genetics (15) 15
chemotherapy, adjuvant (15) 15
patients (15) 15
research (15) 15
therapy (15) 15
tyrosine kinase inhibitors (15) 15
adenocarcinoma - drug therapy (14) 14
expression (14) 14
growth-factor receptor (14) 14
in situ hybridization, fluorescence (14) 14
kaplan-meier estimate (14) 14
non-small cell lung carcinoma (14) 14
quinazolines - therapeutic use (14) 14
crizotinib (13) 13
immunohistochemistry (13) 13
mutations (13) 13
receptor protein-tyrosine kinases - genetics (13) 13
receptor, epidermal growth factor - antagonists & inhibitors (13) 13
respiratory tract diseases (13) 13
tyrosine kinase inhibitor (13) 13
bevacizumab (12) 12
carcinoma (12) 12
carcinoma, non-small-cell lung - secondary (12) 12
follow-up studies (12) 12
gene expression regulation, neoplastic (12) 12
immunotherapy (12) 12
paclitaxel (12) 12
phase-iii trial (12) 12
antibodies, monoclonal - therapeutic use (11) 11
antineoplastic agents - pharmacology (11) 11
clinical trials (11) 11
drug therapy (11) 11
kras (11) 11
lung neoplasms - surgery (11) 11
medicine & public health (11) 11
pemetrexed (11) 11
phase-ii (11) 11
safety (11) 11
tyrosine (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Li, B and Poon, B and Crino, L
TRANSLATIONAL LUNG CANCER RESEARCH, ISSN 2218-6751, 02/2018, Volume 7, Issue Suppl 1, pp. S67 - S69
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 2, pp. 123 - 135
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 38 - 47
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2014, Volume 9, Issue 8, p. e103883
Introduction: Assessment of EGFR mutation in non-small cell lung cancer (NSCLC) patients is mandatory for optimization of pharmacologic treatment. In this... 
BREAST-CANCER | MOLECULAR CHARACTERIZATION | SURVIVAL | THERAPY | DNA | MULTIDISCIPLINARY SCIENCES | PROGRESSION-FREE | FACTOR-RECEPTOR MUTATIONS | DISCORDANCE | EXPRESSION | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Neoplastic Cells, Circulating - pathology | Exons | Humans | Molecular Sequence Data | Neoplastic Cells, Circulating - metabolism | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - diagnosis | Case-Control Studies | Base Sequence | Sensitivity and Specificity | Carcinoma, Non-Small-Cell Lung - pathology | Gene Expression | Biomarkers, Tumor - blood | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Carcinoma, Non-Small-Cell Lung - blood | Biomarkers, Tumor - genetics | High-Throughput Nucleotide Sequencing | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung Neoplasms - diagnosis | Care and treatment | Genetic aspects | Lung cancer, Non-small cell | Analysis | Tumors | Lung cancer | Medical services | Oncology | Metastasis | Kinases | Cancer therapies | Nuclei | Blood | Optimization | Aging | Deoxyribonucleic acid--DNA | Sequences | Epidermal growth factor receptors | Tumor cells | Non-small cell lung carcinoma | Breast cancer | Pharmacology | Real time | Patients | Medicine | Chemotherapy | Hospitals | Biopsy | Experimental design | Diagnostic software | Diagnostic systems | Prostate cancer | Cancer | Deoxyribonucleic acid
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 9, pp. 992 - +
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 05/2017, Volume 317, Issue 18, pp. 1844 - 1853
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Journal Article